« Previous
Next »
Titles
- A sense of déjà vu: the debate surrounding state biosimilar substitution laws1
- Administrative rulemaking1
- Alternative pricing models for remdesivir and other potential treatments for COVID-191
- Association of patient out-of-pocket costs with prescription abandonment and delay in fills of novel oral anticancer agents1